189 related articles for article (PubMed ID: 36461940)
21. An active metabolite of the anti-COVID-19 drug molnupiravir impairs mouse preimplantation embryos at clinically relevant concentrations.
Marikawa Y; Alarcon VB
Reprod Toxicol; 2023 Oct; 121():108475. PubMed ID: 37748715
[TBL] [Abstract][Full Text] [Related]
22. Antiviral Efficacy of Molnupiravir for COVID-19 Treatment.
Bai Y; Shen M; Zhang L
Viruses; 2022 Apr; 14(4):. PubMed ID: 35458493
[TBL] [Abstract][Full Text] [Related]
23. Population pharmacokinetics of molnupiravir in adults with COVID-19: Lack of clinically important exposure variation across individuals.
Bihorel S; Cao Y; Chawla A; Birger R; Maas BM; Gao W; Roepcke S; Sardella S; Humphrey R; Kondragunta S; Jayaraman B; Martinho M; Painter W; Painter G; Holman W; De Anda C; Brown ML; Johnson MG; Paschke A; Rizk ML; Stone JA
CPT Pharmacometrics Syst Pharmacol; 2023 Dec; 12(12):1859-1871. PubMed ID: 37798914
[TBL] [Abstract][Full Text] [Related]
24. Could chlorophyllins improve the safety profile of beta-d-N4-hydroxycytidine versus N-hydroxycytidine, the active ingredient of the SARS-CoV-2 antiviral molnupiravir?
Clark NF; Taylor-Robinson AW; Heimann K
Ther Adv Drug Saf; 2022; 13():20420986221107753. PubMed ID: 35898799
[No Abstract] [Full Text] [Related]
25. Inhibitors of dihydroorotate dehydrogenase cooperate with molnupiravir and N4-hydroxycytidine to suppress SARS-CoV-2 replication.
Stegmann KM; Dickmanns A; Heinen N; Blaurock C; Karrasch T; Breithaupt A; Klopfleisch R; Uhlig N; Eberlein V; Issmail L; Herrmann ST; Schreieck A; Peelen E; Kohlhof H; Sadeghi B; Riek A; Speakman JR; Groß U; Görlich D; Vitt D; Müller T; Grunwald T; Pfaender S; Balkema-Buschmann A; Dobbelstein M
iScience; 2022 May; 25(5):104293. PubMed ID: 35492218
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and anti-SARS-CoV-2 evaluation of lipid prodrugs of β-D-N
Wen ZH; Wang MM; Li LY; Herdewijn P; Snoeck R; Andrei G; Liu ZP; Liu C
Bioorg Chem; 2023 Jun; 135():106527. PubMed ID: 37031504
[TBL] [Abstract][Full Text] [Related]
27. Two short approaches to the COVID-19 drug β-D-
Persaud KE; Sahu RR; Neary MC; Kapdi AR; Lakshman MK
Org Biomol Chem; 2024 Jan; 22(4):735-740. PubMed ID: 38168802
[TBL] [Abstract][Full Text] [Related]
28. Molnupiravir: First Approval.
Syed YY
Drugs; 2022 Mar; 82(4):455-460. PubMed ID: 35184266
[TBL] [Abstract][Full Text] [Related]
29. Transporter modulation of molnupiravir and its metabolite β-D-N4-hydroxycytidine across the blood-brain barrier in a rat.
Chang CH; Peng WY; Lee WH; Yang L; Lin TY; Yang MH; Tsai TH
Commun Med (Lond); 2023 Oct; 3(1):150. PubMed ID: 37857815
[TBL] [Abstract][Full Text] [Related]
30. Molnupiravir inhibits human norovirus and rotavirus replication in 3D human intestinal enteroids.
Santos-Ferreira N; Van Dycke J; Chiu W; Neyts J; Matthijnssens J; Rocha-Pereira J
Antiviral Res; 2024 Mar; 223():105839. PubMed ID: 38373532
[TBL] [Abstract][Full Text] [Related]
31. A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes.
Sanderson T; Hisner R; Donovan-Banfield I; Hartman H; Løchen A; Peacock TP; Ruis C
Nature; 2023 Nov; 623(7987):594-600. PubMed ID: 37748513
[TBL] [Abstract][Full Text] [Related]
32. A Nanopore Based Molnupiravir Sensor.
Jia W; Hu C; Wang Y; Zhang P; Chen HY; Huang S
ACS Sens; 2022 May; 7(5):1564-1571. PubMed ID: 35427117
[TBL] [Abstract][Full Text] [Related]
33. The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model.
Abdelnabi R; Foo CS; Kaptein SJF; Zhang X; Do TND; Langendries L; Vangeel L; Breuer J; Pang J; Williams R; Vergote V; Heylen E; Leyssen P; Dallmeier K; Coelmont L; Chatterjee AK; Mols R; Augustijns P; De Jonghe S; Jochmans D; Weynand B; Neyts J
EBioMedicine; 2021 Oct; 72():103595. PubMed ID: 34571361
[TBL] [Abstract][Full Text] [Related]
34. Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients.
Standing JF; Buggiotti L; Guerra-Assuncao JA; Woodall M; Ellis S; Agyeman AA; Miller C; Okechukwu M; Kirkpatrick E; Jacobs AI; Williams CA; Roy S; Martin-Bernal LM; Williams R; Smith CM; Sanderson T; Ashford FB; Emmanuel B; Afzal ZM; Shields A; Richter AG; Dorward J; Gbinigie O; Van Hecke O; Lown M; Francis N; Jani B; Richards DB; Rahman NM; Yu LM; Thomas NPB; Hart ND; Evans P; Andersson M; Hayward G; Hood K; Nguyen-Van-Tam JS; Little P; Hobbs FDR; Khoo S; Butler C; Lowe DM; Breuer J;
Nat Commun; 2024 Feb; 15(1):1652. PubMed ID: 38396069
[TBL] [Abstract][Full Text] [Related]
35. Molnupiravir: A new candidate for COVID-19 treatment.
Pourkarim F; Pourtaghi-Anvarian S; Rezaee H
Pharmacol Res Perspect; 2022 Feb; 10(1):e00909. PubMed ID: 34968008
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive review on molnupiravir in COVID-19: a novel promising antiviral to combat the pandemic.
Khiali S; Khani E; B Rouy S; Entezari-Maleki T
Future Microbiol; 2022 Mar; 17(5):377-391. PubMed ID: 35199608
[TBL] [Abstract][Full Text] [Related]
37. Uridine-cytidine kinase 2 potentiates the mutagenic influence of the antiviral β-d-N4-hydroxycytidine.
Xu Z; Flensburg C; Bilardi RA; Majewski IJ
Nucleic Acids Res; 2023 Dec; 51(22):12031-12042. PubMed ID: 37953355
[TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of molnupiravir in SARS-CoV-2-infected patients: A real-life experience.
De Vito A; Colpani A; Bitti A; Zauli B; Meloni MC; Fois M; Denti L; Bacciu S; Marcia C; Maida I; Babudieri S; Madeddu G
J Med Virol; 2022 Nov; 94(11):5582-5588. PubMed ID: 35855627
[TBL] [Abstract][Full Text] [Related]
39. A stability indicating RP-HPLC method for determination of the COVID-19 drug molnupiravir applied using nanoformulations in permeability studies.
Reçber T; Timur SS; Erdoğan Kablan S; Yalçın F; Karabulut TC; Neslihan Gürsoy R; Eroğlu H; Kır S; Nemutlu E
J Pharm Biomed Anal; 2022 May; 214():114693. PubMed ID: 35276385
[TBL] [Abstract][Full Text] [Related]
40. Assessing the mitochondrial safety profile of the molnupiravir active metabolite, β-d-N4-hydroxycytidine (NHC), in the physiologically relevant HepaRG model.
Kiy RT; Khoo SH; Chadwick AE
Toxicol Res (Camb); 2024 Feb; 13(1):tfae012. PubMed ID: 38328743
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
